1
|
Parmar K, Yagneshwari N. Gastroretentive Chronopharmaceutical Formulation of Lafutidine for Early Morning Acid Breakthrough. PHARMACOPHORE 2022. [DOI: 10.51847/kwfmn53pu5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
2
|
Gowthami B, Krishna SVG, Rao DS. Application of coating technology to chronotherapeutic drug delivery systems: Recent publications and patents. CURRENT RESEARCH IN PHARMACOLOGY AND DRUG DISCOVERY 2021; 2:100015. [PMID: 34909650 PMCID: PMC8663946 DOI: 10.1016/j.crphar.2021.100015] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 01/19/2021] [Accepted: 01/19/2021] [Indexed: 11/30/2022] Open
Abstract
In general, extended release systems have the ability to maintain the drug concentration with in therapeutic range for prolonged period of time, but this may not be the primary requisite for circadian rhythm diseases like asthma, hypertension and rheumatoid arthritis, etc. They require prompt release of drug as per the disease condition, which can be achieved by programmed lag time. Chronotherapeutic drug delivery systems (CDDS) can be achieved by several methods, coating is one amongst them. Though the coating process is complex in terms of methodology, solubility issues and difficulty in achieving the uniform coating, many researchers were successfully employed in development of CDDS. A scientific prospection was made from 2010 to 2020 using PubMed database. Apart from exploration of publication data, we attempt to brief about classification of patents and concordance. The scrutiny also highlights the patents filed on chronotherapeutic systems, focusing particularly on coating technologies. The review is concluded the successful application of coating technology to develop CDDS, as evident from vast number of publications and patents filed.
Collapse
Affiliation(s)
- Buduru Gowthami
- Faculty of Pharmaceutical Sciences, J.N.T.U.A Ananthapuramu, 515002, Andhra Pradesh, India
| | - S V Gopala Krishna
- Vagdevi College of Pharmacy and Research Centre, Brahmadevam, Nellore, 524001, Andhra Pradesh, India
| | - D Subba Rao
- Dept. of Chemical Engineering, J.N.T.U.A Ananthapuramu, 515002, Andhra Pradesh, India
| |
Collapse
|
3
|
Zhou Y, Li L, Liu Z, Wang Q, Zhou Q, Zhou W. Development and evaluation of zopiclone compression coated tablet for time-controlled pulse release: Mechanism and in vivo study. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2020.101714] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Application of statistical design on the early development of sustained-release tablet containing ivy leaf extract. J Drug Deliv Sci Technol 2019. [DOI: 10.1016/j.jddst.2019.101319] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
5
|
Liu T, Shi Y, Li J, Jiang W, Yin T, Zhang Y, He H, Wang Y, Tang X. Nifedipine di-matrix depot tablets prepared by compression coating for obtaining zero-order release. Drug Dev Ind Pharm 2018; 44:1426-1433. [DOI: 10.1080/03639045.2018.1458859] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Ting Liu
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Yanan Shi
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Jinlong Li
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Wei Jiang
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Tian Yin
- School of Functional food and Wine, Shenyang Pharmaceutical University, Shenyang, China
| | - Yu Zhang
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Haibing He
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Yanjiao Wang
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Xing Tang
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| |
Collapse
|
6
|
Lei Z, Liu Q, Yang B, Khaliq H, Ahmed S, Fan B, Cao J, He Q. Evaluation of Marbofloxacin in Beagle Dogs After Oral Dosing: Preclinical Safety Evaluation and Comparative Pharmacokinetics of Two Different Tablets. Front Pharmacol 2018; 9:306. [PMID: 29692725 PMCID: PMC5903334 DOI: 10.3389/fphar.2018.00306] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Accepted: 03/16/2018] [Indexed: 12/29/2022] Open
Abstract
The current study evaluates a tested marbofloxacin tablet (MBT) (Petsen), in terms of bioavailability and pharmacokinetics (PK) in a comparison of the commercialized and standard tablet (Marbocyl) in beagle dogs. Four different bacterial species were selected for the determination of the minimal inhibitory concentration (MIC) against marbofloxacin (MBF). Target animal safety studies were conducted with a wide spectrum of dosages of Petsen. Pharmacokinetics and bioavailability of Petsen were observed after the oral administration of a recommended dosage of 2 mg/kg. The MIC90 of MBF against Staphylococcus aureus, Escherichia coli, Pasteurella multocida, and Streptococcus were 2.00, 4.00, 0.25, and 0.50 μg/ml, respectively. These results showed that the MBT has an expected antimicrobial activity in vitro. The main parameters of t1/2β, Clb, AUC0−∞, Cmax, and Ke were 22.14 h, 0.15 L/h, 13.27 μg.h/ml, 0.95 μg/ml, 0.09 h−1, and 16.47 h, 0.14 L/h, 14.10 μg.h/ml, 0.97 μg/ml, 0.11 h−1 after the orally administrated Petsen and Marbocyl, while no biologically significant changes and toxicological significance have been found by their comparison. These findings indicate that the Petsen had a slow elimination, high bioavailability and kinetically similar to the commercialized Marbocyl. Furthermore, no statistically significant differences were distinguished on the continuous gradient dosages of 2, 6, and 10 mg/kg in the term of the clinical presentation. The present study results displayed that the tested MBT (Petsen) was safe, with limited toxicity, which was similar to the commercialized tablet (Marbocyl), could provide an alternative MBT as a veterinary medicine in beagle dogs.
Collapse
Affiliation(s)
- Zhixin Lei
- State Key Laboratory of Agriculture Microbiology, College of Veterinary Medicine, Huazhong Agriculture University, Wuhan, China.,Department of Veterinary Pharmacology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China.,National Reference Laboratory of Veterinary Drug Residues and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agriculture University, Wuhan, China
| | - Qianying Liu
- State Key Laboratory of Agriculture Microbiology, College of Veterinary Medicine, Huazhong Agriculture University, Wuhan, China.,Department of Veterinary Pharmacology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China.,National Reference Laboratory of Veterinary Drug Residues and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agriculture University, Wuhan, China
| | - Bing Yang
- State Key Laboratory of Agriculture Microbiology, College of Veterinary Medicine, Huazhong Agriculture University, Wuhan, China.,Department of Veterinary Pharmacology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
| | - Haseeb Khaliq
- Department of Veterinary Pharmacology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
| | - Saeed Ahmed
- Department of Veterinary Pharmacology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China.,National Reference Laboratory of Veterinary Drug Residues and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agriculture University, Wuhan, China
| | - Bowen Fan
- State Key Laboratory of Agriculture Microbiology, College of Veterinary Medicine, Huazhong Agriculture University, Wuhan, China.,Department of Veterinary Pharmacology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China
| | - Jiyue Cao
- Department of Veterinary Pharmacology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China.,National Reference Laboratory of Veterinary Drug Residues and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agriculture University, Wuhan, China
| | - Qigai He
- State Key Laboratory of Agriculture Microbiology, College of Veterinary Medicine, Huazhong Agriculture University, Wuhan, China
| |
Collapse
|
7
|
Chen K, Wang Y, Gai X, Wang H, Li Y, Wen H, Pan W, Yang X. Design of a Time-Controlled Pulsatile Release System for Propranolol Using the Dry-Coated Method: In Vitro and In Vivo Evaluation. AAPS PharmSciTech 2017; 18:2683-2690. [PMID: 28281210 DOI: 10.1208/s12249-017-0746-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2016] [Accepted: 02/19/2017] [Indexed: 11/30/2022] Open
Abstract
The objective of this study was to design a time-controlled pulsatile release (TCPR) system containing propranolol (PNH) as an active pharmaceutical ingredient. Here, the developed dosage forms were coated with hydroxypropyl-methylcellulose (HPMC) and other excipients as barrier layer using dry-coated technology. The influence of HPMC, microcrystalline cellulose (MCC), and lactose in the outer coating and the coating weight on drug release were investigated. Then, a three-factor, five-level central composite design (CCD) and response surface method were used to optimize the formula of the coating. After data processing, the optimal prescription was found to be as follows: HPMC E50(X1) 86.2 mg, MCC(X2) 43.8 mg, and lactose (X3) 21.3 mg in the coating. Moreover, the in vitro tests showed that the optimized formulation of TCPR had a lag time of 4 h followed by a 4-h drug release. Also, determination of the extent of erosion of the TCPR tablets revealed that the lag time is related to the coating erosion speed. The in vivo test in beagle dogs and comparison of the parameters for the TCPR tablets and reference preparations showed significant differences for Tmax (7.83 ± 0.408 and 2 ± 0.00) and Cmax (185.45 ± 28.561 and 587 ± 45.27 ng/ml) but no significant differences in the AUC0-∞ (1757.876 ± 208.832 and 1779.69 ± 229.02 ng h/ml). These results demonstrated that the TCPR tablets successfully prolonged the lag time and controlled the release of propranolol.
Collapse
|
8
|
Foppoli AA, Maroni A, Cerea M, Zema L, Gazzaniga A. Dry coating of solid dosage forms: an overview of processes and applications. Drug Dev Ind Pharm 2017; 43:1919-1931. [DOI: 10.1080/03639045.2017.1355923] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Anastasia Anna Foppoli
- Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche ‘M.E. Sangalli’, Università degli Studi di Milano, Milano, Italy
| | - Alessandra Maroni
- Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche ‘M.E. Sangalli’, Università degli Studi di Milano, Milano, Italy
| | - Matteo Cerea
- Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche ‘M.E. Sangalli’, Università degli Studi di Milano, Milano, Italy
| | - Lucia Zema
- Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche ‘M.E. Sangalli’, Università degli Studi di Milano, Milano, Italy
| | - Andrea Gazzaniga
- Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche ‘M.E. Sangalli’, Università degli Studi di Milano, Milano, Italy
| |
Collapse
|
9
|
Jagdale S, Chandekar A. Optimization of Chitosan and Cellulose Acetate Phthalate Controlled Delivery of Methylprednisolone for Treatment of Inflammatory Bowel Disease. Adv Pharm Bull 2017; 7:203-213. [PMID: 28761822 PMCID: PMC5527234 DOI: 10.15171/apb.2017.025] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2016] [Revised: 12/20/2016] [Accepted: 04/30/2017] [Indexed: 01/07/2023] Open
Abstract
Purpose: Inflammatory bowel disease (IBD) is a chronic, relapsing and often life-long disorder. The best way to tackle IBD is to develop a site targeted drug delivery. Methylprednisolone is a potent anti-inflammatory steroid. The relative potency of methylprednisolone to hydrocortisone is at least four is to one. The aim of the present research was to develop a colon targeted drug delivery for treatment of IBD. Methods: Compression coated drug delivery system was designed and optimised. Core tablet contained drug, croscarmellose sodium (CCS-superdisintegrant), avicel (binder) and dicalcium phosphate (diluent). Design of experiment with 32 factorial design was applied for optimization of compression coated delivery. Chitosan and cellulose acetate phthalate were chosen as independent variables. Swelling index, hardness and % drug release were dependant variables. Results: Core tablet (C5 batch) containing 2.15% CCS showed disintegration in less than 10sec. FTIR, UV and DSC study had shown absence of any significant physical and chemical interaction between drug and polymers. F8 was found to be optimised formulation. F8 contained 35% chitosan and 17.5% cellulose acetate phthalate. It showed drug release of 86.3% ± 6.1%, hardness 6.5 ± 1.5 and lag time 7 hrs. Simulated media drug release was 97.51 ± 8.6% with 7.5 hrs lag time. The results confirmed that the lag time was highly affected by the coating of the polymers as well as the concentration of the superdisintegrant used in core tablet. Conclusion: In-vitro and in-vivo results confirmed a potential colon targeted drug therapy for treatment of IBD.
Collapse
Affiliation(s)
- Swati Jagdale
- Department of Pharmaceutics, MAEER’s Maharashtra Institute of Pharmacy, MIT Campus, S. No. 124, Kothrud, Pune 411038, Savitribai Phule Pune University, India
| | | |
Collapse
|
10
|
Song Y, Peressin K, Wong PY, Page SW, Garg S. Key Considerations in Designing Oral Drug Delivery Systems for Dogs. J Pharm Sci 2016; 105:1576-1585. [PMID: 27056627 DOI: 10.1016/j.xphs.2016.03.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2015] [Revised: 02/19/2016] [Accepted: 03/07/2016] [Indexed: 10/22/2022]
Abstract
The present review discusses the pharmaceutical impact of the anatomy and physiology of the canine gastrointestinal tract to provide a comprehensive guide to the theories and challenges associated with the development of oral drug delivery systems for dogs. Novel pharmaceutical technologies applied to veterinary drugs are discussed indicating the advantages and benefits for animals. There are currently immense research and development efforts being funneled into novel canine health products. Such products are being used to overcome limitations of drugs that display site-dependent absorption or possess poor biopharmaceutical properties. Techniques that are employed to increase bioavailability of the Biopharmaceutics Classification System class II drugs are discussed in this article. Furthermore, an overview of palatable oral formulations for dog care is provided as an approach to easy administration. In vitro and in vivo evaluation and correlation of oral drug formulations in dogs are also addressed. This article assesses the outlook of canine oral drug development recognizing substantial growth forecasts of the dog care market.
Collapse
Affiliation(s)
- Yunmei Song
- School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA 5000, Australia
| | - Karl Peressin
- School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA 5000, Australia
| | - Pooi Yin Wong
- School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA 5000, Australia
| | | | - Sanjay Garg
- School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA 5000, Australia.
| |
Collapse
|
11
|
Maroni A, Zema L, Cerea M, Foppoli A, Palugan L, Gazzaniga A. Erodible drug delivery systems for time-controlled release into the gastrointestinal tract. J Drug Deliv Sci Technol 2016. [DOI: 10.1016/j.jddst.2015.10.001] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Aburahma MH, Badr-Eldin SM. Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals. Expert Opin Drug Deliv 2014; 11:1865-83. [PMID: 25152197 DOI: 10.1517/17425247.2014.935335] [Citation(s) in RCA: 119] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Compritol® 888 ATO is a lipid excipient that is generally used in cosmetic industry as a surfactant, emulsifying agent and viscosity-inducing agent in emulsions or creams. Based on its chemical composition, Compritol 888 ATO is a blend of different esters of behenic acid with glycerol. AREAS COVERED Recently, there has been great interest in the multiple roles that Compritol 888 ATO plays in various pharmaceutical delivery systems. Accordingly, this review aimed at summarizing the current and potential applications of Compritol 888 ATO in various drug delivery areas. EXPERT OPINION Different researches have highlighted the feasibility of using Compritol 888 ATO as a lubricant or coating agent for oral solid dosage formulations. It has also been explored as a matrix-forming agent for controlling drug release. At present, the most common pharmaceutical application of Compritol 888 ATO is in lipid-based colloidal drug delivery system such as solid lipid microparticles, solid lipid nanoparticles and nanostructured lipid carriers. Although, Compritol 888 ATO has acceptable regulatory and safety profiles and although the number of articles that emphasize on its applicability as an innovative excipient in pharmaceutical technology is continuously increasing, it is not widely used in the pharmaceutical market products and its use is limited to its sustain release ability in extended release tablets.
Collapse
Affiliation(s)
- Mona H Aburahma
- King Abdulaziz University, Faculty of Pharmacy, Department of Pharmaceutics and Industrial Pharmacy , Jeddah 21589 , Saudi Arabia
| | | |
Collapse
|
13
|
Taha EI. Bioavailability assessment of hydroxymethylglutaryl coenzyme A reductase inhibitor utilizing pulsatile drug delivery system: a pilot study. Drug Deliv 2014; 23:2139-2143. [DOI: 10.3109/10717544.2014.947049] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Ehab I. Taha
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Saudi Arabia and
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
| |
Collapse
|
14
|
Jagdale SC, Suryawanshi VM, Pandya SV, Kuchekar BS, Chabukswar AR. Development of press-coated, floating-pulsatile drug delivery of lisinopril. Sci Pharm 2014; 82:423-40. [PMID: 24959410 PMCID: PMC4065132 DOI: 10.3797/scipharm.1301-27] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2013] [Accepted: 04/14/2014] [Indexed: 01/09/2023] Open
Abstract
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor, primarily used for the treatment of hypertension, congestive heart failure, and heart attack. It belongs to BCS class III having a half-life of 12 hrs and 25% bioavailability. The purpose of the present work was to develop a press-coated, floating-pulsatile drug delivery system. The core tablet was formulated using the super-disintegrants crosprovidone and croscarmellose sodium. A press-coated tablet (barrier layer) contained the polymer carrageenan, xanthan gum, HPMC K4M, and HPMC K15M. The buoyant layer was optimized with HPMC K100M, sodium bicarbonate, and citric acid. The tablets were evaluated for physical characteristics, floating lag time, swelling index, FTIR, DSC, and in vitro and in vivo behavior. The 5% superdisintgrant showed good results. The FTIR and DSC study predicted no chemical interactions between the drug and excipients. The formulation containing xanthan gum showed drug retaining abilities, but failed to float. The tablet containing HPMC K15M showed a high swelling index. The lag time for the tablet coated with 200 mg carrageenan was 3±0.1 hrs with 99.99±1.5% drug release; with 140 mg HPMC K4M, the lag time was 3±0.1 hrs with 99.71±1.2% drug release; and with 120 mg HPMC K15M, the lag time was 3±0.2 hrs with 99.98±1.7% drug release. The release mechanism of the tablet followed the Korsmeyer-Peppas equation and a first-order release pattern. Floating and lag time behavior have shown good in vitro and in vivo correlations.
Collapse
Affiliation(s)
- Swati C Jagdale
- Department of Pharmaceutics, MAEER's Maharashtra Institute of Pharmacy, Kothrud, Pune, 411 038, Maharashtra, India
| | - Vishnu M Suryawanshi
- Department of Pharmaceutics, MAEER's Maharashtra Institute of Pharmacy, Kothrud, Pune, 411 038, Maharashtra, India
| | - Sudhir V Pandya
- Quality Assurance, Nulife Pharmaceuticals, Pimpri, 411 018 Pune, Maharashtra, India
| | - Bhanudas S Kuchekar
- Department of Pharmaceutical Chemistry, MAEER's Maharashtra Institute of Pharmacy, Kothrud, Pune, 411 038, Maharashtra, India
| | - Aniruddha R Chabukswar
- Department of Pharmaceutical Chemistry, MAEER's Maharashtra Institute of Pharmacy, Kothrud, Pune, 411 038, Maharashtra, India
| |
Collapse
|
15
|
Optimization studies on compression coated floating-pulsatile drug delivery of bisoprolol. BIOMED RESEARCH INTERNATIONAL 2013; 2013:801769. [PMID: 24367788 PMCID: PMC3842062 DOI: 10.1155/2013/801769] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/05/2013] [Revised: 08/19/2013] [Accepted: 09/24/2013] [Indexed: 11/17/2022]
Abstract
The purpose of the present work was to design and optimize compression coated floating pulsatile drug delivery systems of bisoprolol. Floating pulsatile concept was applied to increase the gastric residence of the dosage form having lag phase followed by a burst release. The prepared system consisted of two parts: a core tablet containing the active ingredient and an erodible outer shell with gas generating agent. The rapid release core tablet (RRCT) was prepared by using superdisintegrants with active ingredient. Press coating of optimized RRCT was done by polymer. A 3² full factorial design was used for optimization. The amount of Polyox WSR205 and Polyox WSR N12K was selected as independent variables. Lag period, drug release, and swelling index were selected as dependent variables. Floating pulsatile release formulation (FPRT) F13 at level 0 (55 mg) for Polyox WSR205 and level +1 (65 mg) for Polyox WSR N12K showed lag time of 4 h with >90% drug release. The data were statistically analyzed using ANOVA, and P < 0.05 was statistically significant. Release kinetics of the optimized formulation best fitted the zero order model. In vivo study confirms burst effect at 4 h in indicating the optimization of the dosage form.
Collapse
|
16
|
A novel multilayered multidisk oral tablet for chronotherapeutic drug delivery. BIOMED RESEARCH INTERNATIONAL 2013; 2013:569470. [PMID: 24024200 PMCID: PMC3762207 DOI: 10.1155/2013/569470] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/30/2013] [Accepted: 07/15/2013] [Indexed: 12/14/2022]
Abstract
A Multilayered Multidisk Tablet (MLMDT) comprising two drug-loaded disks enveloped by three drug-free barrier layers was developed for use in chronotherapeutic disorders, employing two model drugs, theophylline and diltiazem HCl. The MLMDT was designed to achieve two pulses of drug release separated by a lag phase. The polymer disk comprised hydroxyethylcellulose (HEC) and ethylcellulose (EC) granulated using an aqueous dispersion of EC. The polymeric barrier layers constituted a combination of pectin/Avicel (PBL) (1st barrier layer) and hydroxypropylmethylcellulose (HPMC) (HBL1 and HBL2) as the 2nd and 3rd barrier layers, respectively. Sodium bicarbonate was incorporated into the diltiazem-containing formulation for delayed drug release. Erosion and swelling studies confirmed the manner in which the drug was released with theophylline formulations exhibiting a maximum swelling of 97% and diltiazem containing formulations with a maximum swelling of 119%. FTIR spectra displayed no interactions between drugs and polymers. Molecular mechanics simulations were undertaken to predict the possible orientation of the polymer morphologies most likely affecting the MLMDT performance. The MLMDT provided two pulses of drug release, separated by a lag phase, and additionally it displayed desirable friability, hardness, and uniformity of mass indicating a stable formulation that may be a desirable candidate for chronotherapeutic drug delivery.
Collapse
|
17
|
Men J, Gao B, Wang R, Li C. CPVA Grafted Poly(sodium 4-styrene sulfonate) and Studies on its Colon Specific for Chronotherapy of Nocturnal Asthma. JOURNAL OF MACROMOLECULAR SCIENCE PART A-PURE AND APPLIED CHEMISTRY 2013. [DOI: 10.1080/10601325.2013.829671] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
18
|
Vemula SK, Veerareddy PR. Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. Expert Opin Drug Deliv 2012. [DOI: 10.1517/17425247.2013.743528] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
19
|
Patil AS, Dandagi PM, Masthiholimath VS, Gadad AP, Najwade BK. Development and characterization of chronomodulated drug delivery system of captopril. Int J Pharm Investig 2012; 1:227-33. [PMID: 23071948 PMCID: PMC3465150 DOI: 10.4103/2230-973x.93010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Background: Hypertension shows circadian rhythm that there is a rise in pressure from the time of waking or before (about 4 to 8 a.m.), in most people. Conventional drug delivery system of captopril is inappropriate for the delivery of drug, as they cannot be administered just before the symptoms are worsened, because during this time the patients are asleep, bedtime dosing of captopril will not provide a therapeutic plasma drug concentration at the early hours of morning because of poor pharmacokinetic profile and shorter half-life of 1.9 hours. Thus, this study attempts to design and evaluate a chronomodulated pulsatile drug delivery system of captopril which was aimed to release the drug after a lag time of 6 hours. Materials and Methods: Present delivery system was prepared by rupturable coating method. The core containing captopril as a bioactive compound were prepared by direct compression method and then coated sequentially with an inner swelling layer containing hydrocolloid HPMC E5 and an outer rupturable layer consisted of Eudragit RL/RS (1 : 1). Total 12 formulations with different levels of inner swelling layer and outer polymeric layer were prepared and subjected to various processing and formulative parameters like the effect of core composition, level of swelling layer, and rupturable coating on lag time was investigated. In vitro drug release and rupture tests were performed using United States Pharmacopoeia paddle method at 50 rpm in 0.1N HCl and phosphate buffer of pH 6.8. Results: The results showed that as the amount of inner swelling layer increases, the lag time decreases and as the Eudragit coating level increases, the lag time increases and percent water uptake of time-dependent pulsatile release system decreases. The presence of an osmotic agent and effervescent agent helped in shortening of lag time. Conclusion: The system was found to be satisfactory in terms of release of the drug after the lag time of 6 hours.
Collapse
Affiliation(s)
- Archana S Patil
- Department of Pharmaceutics, R.C. College of Pharmacy, Belgaum, India
| | | | | | | | | |
Collapse
|
20
|
Petrovic AA, Petricevic SM, Ristic SM, Ibric SR, Simic SS, Djuric ZR, Popovic RB. Preliminary evaluation of thein vitrorelease andin vivoabsorption in rabbits of the modified-release dosage forms. Drug Dev Ind Pharm 2012; 39:889-900. [DOI: 10.3109/03639045.2012.713364] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
21
|
On-off pulsed oral drug-delivery systems: a possible tool for drug delivery in chronotherapy. Ther Deliv 2012; 2:1199-214. [PMID: 22833913 DOI: 10.4155/tde.11.91] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Circadian rhythms regulate most body functions and are important factors to consider when administering drugs. The existence of circadian rhythms in nature and their influences on human biological systems have given rise to the concept of chronotherapy, which is the science of delivering drugs in a synchronized manner with the rhythm-dependent circadian variation inherent in the human body. The safety and efficacy of a drug can be improved by matching the peak plasma concentration during a 24 h period of the rhythms. An on-off pulsed (pulsatile or time-controlled) release drug-delivery system offers rapid and transient release; stepwise release; and the sustained release of a certain amount of drug within a short time period after a predetermined off-release period according to the circadian rhythm of disease states. These systems deliver the drug at the right time and at an appropriate dosage and are the best approach for chronotherapy. These systems show promise for the optimal therapy of chronic diseases such as asthma, hypertension, myocardial infarction and arthritis, which show a circadian dependency. Various technologies have been adopted to mimic circadian rhythms in physiological functions and diseases. This review focuses on the basic concept of circadian rhythm, chronotherapy and recent advances in the development of on-off pulsed oral drug-delivery systems for optimal therapy.
Collapse
|
22
|
Yassin AEB, Aodah AH, Al-Suwayeh S, Taha EI. Theophylline colon specific tablets for chronotherapeutic treatment of nocturnal asthma. Pharm Dev Technol 2011; 17:712-8. [PMID: 21486185 DOI: 10.3109/10837450.2011.572896] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The ultimate goal is to design a new chronotherapeutic system for theophylline (TPH) with high potential benefits in treating nocturnal asthma. TPH core tablets were prepared by wet granulation using a developed formula. Compression coating over core tablets containing 200 mg TPH was done using granulated chitosan with 10% PVP K30. Different formulae F1, F2 and F3 were prepared using coat weights 260, 300 and 360 mg, respectively. The in vitro release characteristics in both variant pH media mimicking the gastrointestinal media and in media containing rat cecal content were monitored. The in vivo performance of the optimum formula was compared with Avolen(®) SR in Beagle dogs. F3 with high coat thickness exhibited a minimal release after 5-h release study. Both F2 and F3 showed more than 50% drug release after 4 h in the rat cecal medium. This reflects the colon selectivity of the system. The C(max) values were found to be 5.49 ± 0.46 and 5.12 ± 0.85 μg/mL for F3 and Avolen(®) SR, respectively, F3 showed higher mean plasma concentration than Avolen(®) SR from the beginning and continued till 7 h post administration indicating high potential as chronotherapeutic treatment of nocturnal asthma.
Collapse
Affiliation(s)
- Alaa Eldeen B Yassin
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
| | | | | | | |
Collapse
|
23
|
Ghimire M, Hodges LA, Band J, Lindsay B, O’Mahony B, McInnes FJ, Mullen AB, Stevens HN. Correlation between in vitro and in vivo erosion behaviour of erodible tablets using gamma scintigraphy. Eur J Pharm Biopharm 2011; 77:148-57. [DOI: 10.1016/j.ejpb.2010.10.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2010] [Revised: 10/12/2010] [Accepted: 10/18/2010] [Indexed: 01/14/2023]
|
24
|
Oral pulsatile delivery: Rationale and chronopharmaceutical formulations. Int J Pharm 2010; 398:1-8. [DOI: 10.1016/j.ijpharm.2010.07.026] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2010] [Revised: 07/15/2010] [Accepted: 07/17/2010] [Indexed: 12/30/2022]
|
25
|
Barakat NS, Al-Suwayeh SA, Taha EI, Bakry Yassin AE. A new pressure-controlled colon delivery capsule for chronotherapeutic treatment of nocturnal asthma. J Drug Target 2010; 19:365-72. [PMID: 20681754 DOI: 10.3109/1061186x.2010.504264] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The purpose of this study was to prepare a pressure-controlled colon delivery capsule (PCDC) containing theophylline (TPH) dispersion in a lipid matrix as a chronotherapeutic drug delivery system for the treatment of nocturnal asthma. The system was made by film coating using Eudragit S100- based formula over the sealed-hard gelatin capsules containing the drug-lipid dispersion. The lipid formula was composed mainly of Gelucire 33/01 (G33) with different ratios of surfactants (1-10%). The efficiency of the prepared system was evaluated in vitro for its ability to withstand both the gastric and intestinal medium. In addition, the drug plasma concentrations were monitored after single administration to Beagle dogs and compared to that obtained after administration of a reference marketed, generic, sustained-release TPH tablets, Avolen(®) SR. It was found that the optimum lipid formula was GL2 containing 90% G33 and 10% Labrasol. The film-coated capsules showed complete resistance to both the acidic environment (pH 1.2) for 2 hours and phosphate buffer pH 6.8 for 3 hours at 37°C. In vivo evaluation of the TPH-based PCDCs showed longer lag time compared TO the marketed formula followed by sudden increase in TPH blood levels, which recommends the high potential of this system as a chronotherapeutic drug delivery for nocturnal asthma. The prepared PCDCs exhibited a significantly higher C(max) and T(max) and a nonsignificantly different AUC compared with Avolen(®) SR. Higher TPH blood levels from 1 to 8 hours postadministration was detected in the case of the prepared PCDCs.
Collapse
Affiliation(s)
- Nahla S Barakat
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | | | | | | |
Collapse
|